{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T07:49:13Z","timestamp":1791791353511,"version":"4.3.4"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":284,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pain Research and Management"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pregabalin (PGB) is commonly used for postherpetic neuralgia (PHN), but its clinical effectiveness may be limited by insufficient pain relief or adverse events (AEs). Crisugabalin (CGB) is a novel \u03b12\u03b4\u20101 ligand that has demonstrated efficacy in randomized placebo\u2010controlled trials. However, comparative real\u2010world evidence for CGB and PGB remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single\u2010center retrospective cohort study included patients with PHN who completed at least 12\u2009weeks of CGB or PGB monotherapy between January and June 2025. In October 2025, a single structured telephone interview was conducted to retrospectively assess patients\u2019 recalled status at treatment initiation (T0) and at Weeks 1, 4, and 12. Outcomes included the Numerical Rating Scale (NRS), Pittsburgh Sleep Quality Index (PSQI), and the physical and mental component summary scores of the 36\u2010Item Short Form Health Survey (SF\u201036). Linear mixed effects models (LMMs) were designated as the primary analyses and adjusted for age, sex, pain location, pre\u2010enrollment pain duration, hypertension, and diabetes. Repeated measures analysis of variance and the LMM analysis based on inverse probability weighting of propensity scores were performed as sensitivity analysis. Safety outcomes were descriptively assessed among treatment completers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 113 patients were included, including 56 in the CGB group and 57 in the PGB group. In the adjusted LMMs, significant treatment\u2010by\u2010time interactions were observed for NRS scores (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), PSQI scores (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), and SF\u201036 mental component summary scores (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.003), the extent to which these three scores of the CGB group improved over time may be higher than that of the PGB group. The treatment\u2010by\u2010time interactions were not statistically significant for SF\u201036 physical component summary scores (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.377). Sensitivity analyses using repeated measures analysis of variance produced concordant findings for NRS, PSQI, and SF\u201036 mental component scores but not for SF\u201036 physical component scores. At least one AE was reported by 11 of 56 patients in the CGB group and 18 of 57 patients in the PGB group, but there was no overall significant difference in AEs (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.196).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients who completed 12\u2009weeks of treatment, the CGB group was associated with statistical differences to some extent in NRS, PSQI, and SF\u201036 mental component scores than PGB group, and these degree of improvement over time may be more pronounced. Due to the substantial bias in retrospective studies and the relatively small sample size, these findings should be interpreted as exploratory, merely have reference value, and require more confirmation in prospective controlled studies in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1155\/prm\/8540301","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T07:32:44Z","timestamp":1791790364000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Exploratory Retrospective Comparison of Crisugabalin and Pregabalin Among 12\u2010Week Treatment Completers With Postherpetic Neuralgia"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2279-8789","authenticated-orcid":false,"given":"Rui-Tao","family":"Shang","sequence":"first","affiliation":[{"name":"Department of Pain Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine  Nanjing China  nju.edu.cn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9532-2828","authenticated-orcid":false,"given":"Qian-Qian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pain Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine  Nanjing China  nju.edu.cn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pain Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine  Nanjing China  nju.edu.cn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4228-2817","authenticated-orcid":false,"given":"You-Pan","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Pain Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine  Nanjing China  nju.edu.cn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Nan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pain Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine  Nanjing China  nju.edu.cn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Chuan","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Pain Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine  Nanjing China  nju.edu.cn"},{"name":"Department of Pain Nanjing Drum Tower Hospital Affiliated Hospital of Medical School Nanjing University  Nanjing China  nju.edu.cn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Li","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pain Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine  Nanjing China  nju.edu.cn"},{"name":"Department of Pain Nanjing Drum Tower Hospital Affiliated Hospital of Medical School Nanjing University  Nanjing China  nju.edu.cn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2968-2343","authenticated-orcid":false,"given":"Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pain Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine  Nanjing China  nju.edu.cn"},{"name":"Department of Pain Nanjing Drum Tower Hospital Affiliated Hospital of Medical School Nanjing University  Nanjing China  nju.edu.cn"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"e_1_2_12_1_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-017-0091-4"},{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-012-0014-3"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2011.09.2469"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12413"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.02.007"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/jpr.s157856"},{"key":"e_1_2_12_7_2","article-title":"Pregabalin for Neuropathic Pain in Adults","volume":"1","author":"Derry S.","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2017.1384691"},{"key":"e_1_2_12_9_2","doi-asserted-by":"crossref","DOI":"10.1007\/s40263-026-01292-x","article-title":"Is Crisugabalin Signaling the Arrival of a Third Generation of \u03b12\u03b4 Ligands?","author":"Alc\u00e1ntara Montero A.","year":"2026","journal-title":"CNS Drugs"},{"key":"e_1_2_12_10_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.120.000315"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.5c00336"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.3410"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.25614"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-007-0321-2"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(89)90047-4"},{"key":"e_1_2_12_16_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual Framework and Item Selection","volume":"30","author":"Ware J. E.","year":"1992","journal-title":"Medical Care"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1667364"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.3344\/kjp.2015.28.3.177"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1614587"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00938-8"},{"key":"e_1_2_12_21_2","article-title":"Topical Capsaicin (High Concentration) for Chronic Neuropathic Pain in Adults","volume":"1","author":"Derry S.","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.04.014"},{"key":"e_1_2_12_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/mjt.0b013e318250f80e"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-022-00451-4"},{"key":"e_1_2_12_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-025-00745-3"},{"key":"e_1_2_12_26_2","article-title":"Crisugabalin, A Ligand for the \u03b1(2)\u03b4 Subunit of Voltage-Gated Calcium Channels, Exhibits no Obvious Abuse Potential in Rodents","volume":"252","author":"Gou X.","year":"2025","journal-title":"Pharmacology, Biochemistry and Behavior"},{"key":"e_1_2_12_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00581-w"},{"key":"e_1_2_12_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01717-7"},{"key":"e_1_2_12_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-017-0089-y"},{"key":"e_1_2_12_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/aln.0000000000005715"},{"key":"e_1_2_12_31_2","doi-asserted-by":"publisher","DOI":"10.3344\/kjp.2021.34.4.463"},{"key":"e_1_2_12_32_2","doi-asserted-by":"publisher","DOI":"10.3344\/kjp.2021.34.2.210"}],"container-title":["Pain Research and Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/prm\/8540301","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/prm\/8540301","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/prm\/8540301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T07:32:45Z","timestamp":1791790365000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/prm\/8540301"}},"subtitle":[],"editor":[{"given":"Massimiliano","family":"Valeriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/prm\/8540301"],"URL":"https:\/\/doi.org\/10.1155\/prm\/8540301","archive":["Portico"],"relation":{},"ISSN":["1203-6765","1918-1523"],"issn-type":[{"value":"1203-6765","type":"print"},{"value":"1918-1523","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2026-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"8540301"}}